Syzygium aromaticum Reduces Diabetes-induced Glucotoxicity via the NRF2/Glo1 Pathway

Abstract

Advanced glycation end products and methylglyoxal are known to show increased levels in diabetic conditions and induce diverse metabolic disorders. However, the antiglycation ability of the bark of Syzygium aromaticum is not yet studied. In this study, we determined the inhibitory effects of S. aromaticum on AGE formation. Moreover, S. aromaticum showed breakage and inhibitory ability against the formation of AGE-collagen crosslinks. In SV40 MES13 cells, treatment with the S. aromaticum extract significantly ameliorated MG-induced oxidative stress as well as cytotoxicity. Furthermore, in the S. aromaticum extract-treated group, there was a reduction in levels of several diabetic markers, such as blood glucose, kidney weight, and urinary albumin to creatinine ratio in streptozotocin-induced diabetic rats. Treatment with the S. aromaticum extract significantly increased the expression of nuclear factor erythroid 2-related factor 2, a transcription factor involved in the expression of antioxidant enzymes. Moreover, the treatment significantly upregulated the expression of glyoxalase 1 and downregulated the expression of receptor for AGEs. These results suggest that the S. aromaticum extract might ameliorate diabetes-induced renal damage by inhibiting the AGE-induced glucotoxicity and oxidative stress through the Nrf2/Glo1 pathway.

Key words

Syzygium aromaticum - Myrtaceae - diabetes - AGEs - Nrf2

Publication History

Received: 17 February 2020

Accepted after revision: 12 June 2020

Article published online:
09 July 2020

• References

• 1 Kerkeni M, Saïdi A, Bouzidi H, Yahya SB, Hammami M. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvasc Res 2012; 84: 378-383
• 2 Zhu D, Wang L, Zhou Q, Yan S, Li Z, Sheng J, Zhang W. (+)-Catechin ameliorates diabetic nephropathy by trapping methylglyoxal in type 2 diabetic mice. Mol Nutr Food Res 2014; 58: 2249-2260
• 3 Jin X, Yao T, Zhou Z, Zhu J, Zhang S, Hu W, Shen C. Advanced glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE/NF-κB pathway. Biomed Res Int 2015; 2015: 732450 doi:10.1155/2015/732450
• 4 Nowotny K, Jung T, Höhn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5: 194-222
• 5 Lin JA, Wu CH, Lu CC, Hsia SM, Yen GC. Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression. Mol Nutr Food Res 2016; 60: 1850-1864
• 6 Schalkwijk C, Stehouwer CD. Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications and other age-related diseases. Physiol Rev 2019; 100: 407-461
• 7 Zhou Q, Cheng KW, Gong J, Li ET, Wang M. Apigenin and its methylglyoxal-adduct inhibit advanced glycation end products-induced oxidative stress and inflammation in endothelial cells. Biochem Pharmacol 2019; 166: 231-241
• 8 Moraru A, Wiederstein J, Pfaff D, Fleming T, Miller AK, Nawroth P, Teleman AA. Elevated levels of the reactive metabolite methylglyoxal recapitulate progression of type 2 diabetes. Cell Metabol 2018; 27: 926-934
• 9 Giacco F, Du X, DʼAgati VD, Milne R, Sui G, Geoffrion M, Brownlee M. Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 2014; 63: 291-299
• 10 Hanssen NM, Stehouwer CD, Schalkwijk CG. Methylglyoxal stress, the glyoxalase system, and diabetic chronic kidney disease. Curr Opin Nephrol Hypertens 2019; 28: 26-33
• 11 Liu YW, Liu XL, Kong L, Zhang MY, Chen YJ, Zhu X, Hao YC. Neuroprotection of quercetin on central neurons against chronic high glucose through enhancement of Nrf2/ARE/glyoxalase-1 pathway mediated by phosphorylation regulation. Biomed Pharmacother 2019; 109: 2145-2154
• 12 Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res 2016; 118: 1808-1829
• 13 Pulikottil S, Nath S. Potential of clove of Syzygium aromaticum in development of a therapeutic agent for periodontal disease: a review. South Afr Dental J 2015; 70: 108-115
• 14 Issac A, Gopakumar G, Kuttan R, Maliakel B, Krishnakumar I. Safety and anti-ulcerogenic activity of a novel polyphenol-rich extract of clove buds (Syzygium aromaticum L). Food Funct 2015; 6: 842-852
• 15 Sompong W, Adisakwattana S. Inhibitory effect of herbal medicines and their trapping abilities against methylglyoxal-derived advanced glycation end-products. BMC Complement Altern Med 2015; 15: 394
• 16 Al-Sowygh ZH, Ghani SMA, Sergis K, Vohra F, Akram Z. Peri-implant conditions and levels of advanced glycation end products among patients with different glycemic control. Clin Implant Dent Relat Res 2018; 20: 345-351
• 17 Nigro C, Leone A, Raciti GA, Longo M, Mirra P, Formisano P, Beguinot F, Miele C. Methylglyoxal-glyoxalase 1 balance: the root of vascular damage. Int J Mol Sci 2017; 18: 188
• 18 Berlanga J, Cibrian D, Guillén I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequin JF, Ajamieh H, Urquiza D, Ahmed N, Thornalley PJ. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 2005; 109: 83-95
• 19 Al Maruf A, Lip H, Wong H, OʼBrien PJ. Protective effects of ferulic acid and related polyphenols against glyoxal or methylglyoxal-induced cytotoxicity and oxidative stress in isolated rat hepatocytes. Chem Biolo Interact 2015; 234: 96-104
• 20 Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol 2016; 12: 13-26
• 21 Rasch R, Dørup J. Quantitative morphology of the rat kidney during diabetes mellitus and insulin treatment. Diabetologia 1997; 40: 802-809
• 22 Hoefield RA, Kalra PA, Baker PG, Sousa I, Diggle PJ, Gibson MJ, OʼDonoghue DJ, Middleton RJ, New JP. The use of eGFR and ACR to predict decline in renal function in people with diabetes. Nephrol Dial Transplant 2010; 26: 887-892
• 23 Jensen T, Vistisen D, Fleming T, Nawroth P, Rossing P, Jørgensen M, Lauritzen T, Sandbaek A, Witte DR. Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus. Diabet Med 2016; 33: 1625-1631
• 24 Rodrigues L, Matafome P, Crisóstomo J, Santos-Silva D, Sena C, Pereira P, Seiça R. Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation. J Physiol Biochem 2014; 70: 173-184
• 25 Reiniger N, Lau K, McCalla D, Eby B, Cheng B, Lu Y, Qu W, Quadri N, Ananthakrishnan R, Furmansky M, Rosario R, Song F, Rai V, Weinberg A, Friedman R, Ramasamy R, DʼAgati V, Schmidt AM. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010; 59: 2043-2054
• 26 Tomino Y, Hagiwara S, Gohda T. AGE–RAGE interaction and oxidative stress in obesity-related renal dysfunction. Kidney Int 2011; 80: 133-135
• 27 Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH, Kunsch C. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 2006; 290: H1862-H1870
• 28 Xue M, Rabbani N, Momiji H, Imbasi P, Anwar MM, Kitteringham N, Park BK, Souma T, Moriguchi T, Yamamoto M, Thornalley PJ. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J 2012; 443: 213-222
• 29 Zhang S, Liang X, Zheng X, Huang H, Chen X, Wu K, Wang B, Ma S. Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma. Int J Clin Exp Pathol 2014; 7: 2079-2090
• 30 Do M, Hur J, Choi J, Kim Y, Park HY, Ha S. Spatholobus suberectus ameliorates diabetes-induced renal damage by suppressing advanced glycation end products in db/db mice. Int J Mol Sci 2018; 19: 2774